Literature DB >> 14761115

Longitudinal evaluation of GCF IFN-gamma levels and periodontal status in HIV+ patients.

T Alpagot1, K Font, A Lee.   

Abstract

BACKGROUND/AIM: Loss of periodontal support and related tooth loss is a common finding among HIV+ patients. The etiology of this destruction may be an increase in the levels of pro-inflammatory cytokines and subsequent increase in periodontal disease activity. The purpose of this study was to investigate the associations between gingival crevicular fluid interferon gamma (GCF IFN-gamma) and clinical measures of periodontal disease in HIV+ individuals. We monitored GCF IFN-gamma and periodontal status of selected sites in 33 HIV+ subjects over a 6-month period.
METHOD: Clinical measurements including gingival index, plaque index, bleeding on probing, probing depth, attachment loss (AL), and GCF samples were taken from four lower incisors and the upper right posterior sextant of each patient at baseline and 6-month visits by means of sterile paper strips. GCF levels of IFN-gamma were determined by sandwich ELISA assays. A progressing site was defined as a site that had 2 mm or more AL during the 6-month study period.
RESULTS: Twenty-five of the 264 examination sites showed 2 mm or more clinical AL during the 6-month study period. Significantly higher GCF levels of IFN-gamma were found at progressing sites than in nonprogressing sites (p < 0.001). GCF levels of IFN-gamma were highly correlated with clinical measurements taken at baseline and 6-month visits (0.001<p<0.01).
CONCLUSION: These data indicate that sites with high GCF levels of IFN-gamma are at significantly greater risk for progression of periodontitis in HIV+ patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14761115     DOI: 10.1034/j.1600-051x.2003.00403.x

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  7 in total

1.  Supernatants from oral epithelial cells and gingival fibroblasts modulate human immunodeficiency virus type 1 promoter activation induced by periodontopathogens in monocytes/macrophages.

Authors:  O A González; J L Ebersole; C B Huang
Journal:  Mol Oral Microbiol       Date:  2010-04       Impact factor: 3.563

Review 2.  Current trends and new developments in HIV research and periodontal diseases.

Authors:  Mark I Ryder; Caroline Shiboski; Tzy-Jyun Yao; Anna-Barbara Moscicki
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 7.589

3.  Effects of periodontal therapy on GCF cytokines in generalized aggressive periodontitis subjects.

Authors:  Ana Paula de Lima Oliveira; Marcelo de Faveri; Lauren Christine Gursky; Maria Josefa Mestnik; Magda Feres; Anne D Haffajee; Sigmund S Socransky; Ricardo Palmier Teles
Journal:  J Clin Periodontol       Date:  2011-11-30       Impact factor: 8.728

Review 4.  Oral infectious diseases: a potential risk factor for HIV virus recrudescence?

Authors:  O A González; J L Ebersole; C B Huang
Journal:  Oral Dis       Date:  2009-04-02       Impact factor: 3.511

5.  Longitudinal evaluation of prostaglandin E2 (PGE2) and periodontal status in HIV+ patients.

Authors:  Tamer Alpagot; John Remien; Mouchumi Bhattacharyya; Krystyna Konopka; William Lundergan; Nejat Duzguneş
Journal:  Arch Oral Biol       Date:  2007-06-27       Impact factor: 2.633

6.  Biomarkers of oral inflammation in perinatally HIV-infected and perinatally HIV-exposed, uninfected youth.

Authors:  Anna-Barbara Moscicki; Tzy-Jyun Yao; Jonathan S Russell; Sepideh Farhat; Mark Scott; Larry Magpantay; Gordana Halec; Caroline H Shiboski; Mark I Ryder
Journal:  J Clin Periodontol       Date:  2019-09-05       Impact factor: 8.728

7.  Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy.

Authors:  Medini K Annavajhala; Sabrina D Khan; Sean B Sullivan; Jayesh Shah; Lauren Pass; Karolina Kister; Heather Kunen; Victor Chiang; Gwennaëlle C Monnot; Christopher L Ricupero; Rebecca A Mazur; Peter Gordon; Annemieke de Jong; Sunil Wadhwa; Michael T Yin; Ryan T Demmer; Anne-Catrin Uhlemann
Journal:  mSphere       Date:  2020-02-05       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.